News
-
-
PRESS RELEASE
Jaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 PM Eastern Regarding Q1 2025 Financials & Corporate Updates
Jaguar Health, Inc. to file Q1 2025 Earnings Report on May 15, 2025 and conduct investor webcast. Focus on pharmaceuticals from rainforest plants for gastrointestinal distress -
-
PRESS RELEASE
Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs
Jaguar Health, Inc. celebrates FDA conditional approval of Canalevia®-CA1 prescription drug for chemotherapy-induced diarrhea in dogs, highlighting National Pet Cancer Awareness Month and supportive cancer care initiatives -
-
-
-
PRESS RELEASE
Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% - Potential to Modify Disease
Jaguar Health's crofelemer shows promise in reducing TPN needs for MVID and SBS-IF patients. Investor webcast to review proof-of-concept study results presented at ELITE PED-GI Congress -
-
PRESS RELEASE
REMINDER: Jaguar Health Hosting April 30 Investor Webcast to Present Initial Results from Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Jaguar Health investor webcast to review crofelemer impact on MVID and SBS-IF patients. No approved treatments for MVID, study presented by Dr. Miqdady at ELITE PED-GI Congress
